Peptide therapy TikTok claims: separating hype from human data

What did @lifeofrlj actually say?

The creator describes a two-week loading protocol for Melanotan II (which they call "Milano Tantu"), starting at roughly 150 micrograms and working up to approximately 500 micrograms daily, timed around tanning bed sessions or taken before bed on off-days. After the loading phase, they report dropping to a maintenance dose of "three to five units" once or twice a month, paired with a single 12-minute tanning bed session.

Their framing is practical and personal: pale skin, difficulty tanning, and a desire to maintain color with minimal UV exposure. They're not pitching this as a medical treatment. They're describing a cosmetic routine. That context matters when evaluating what they got right and what they glossed over.

Does the science back this up?

Partially, but the parts it backs up are also the parts that come with serious safety warnings the creator didn't mention. Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds melanocortin receptors, primarily MC1R, and does stimulate melanogenesis, meaning it genuinely increases skin pigmentation. That mechanism is real and well-documented.

A 2000 study by Dorr et al. published in the Journal of Investigative Dermatology confirmed that Melanotan II produced dose-dependent increases in skin pigmentation in human subjects. So the core claim, that this peptide increases tanning, is not fabricated.

However, the same research and subsequent pharmacovigilance work have identified consistent side effects: nausea, facial flushing, spontaneous erections in men, and fatigue are among the most commonly reported. Langan et al. (2015, British Journal of Dermatology) flagged concerns about Melanotan II's association with melanocytic lesion changes and potential melanoma risk. The creator mentions none of this.

What did they get wrong (or right)?

Credit where it's due: the dosing math is roughly consistent with what appears in the research literature. Dorr et al. used doses in the range of 0.01 mg/kg, which for an average adult lands near the 500-700 microgram range. Starting low and titrating up is a sensible approach to managing side effects, and the creator's logic of pairing it with UV exposure to activate melanin production is mechanistically sound.

What they got wrong, or more precisely what they omitted, is significant. Melanotan II is not approved by the FDA or any major regulatory body for cosmetic or therapeutic use. It is not legally available as a pharmaceutical product in the United States. The creator doesn't acknowledge this. They also don't mention that changes to existing moles or new lesion growth have been reported by users, a finding serious enough that the British Journal of Dermatology published a case series on it (Langan et al., 2015). Describing a monthly tanning bed session as a casual maintenance routine without noting the compounded UV-plus-melanocortin-receptor stimulation risk is a real gap.

What should you actually know?

Melanotan II has a real pharmacological mechanism and measurable tanning effects. That part of the creator's claim is supported by evidence. But it is an unregulated, unscheduled research compound with no approved human dosing guidelines, no standardized manufacturing oversight, and a side effect profile that includes both short-term issues like nausea and longer-term concerns about melanocytic changes.

The tanning bed component adds another layer of risk. UV exposure is itself a documented carcinogen (IARC Group 1 classification). Combining systemic melanocortin receptor stimulation with UV exposure hasn't been studied in long-term controlled trials. The interaction is not well understood.

• Melanotan II is not FDA-approved. Purchasing it for human use exists in a legal gray area in the US.
• Nausea, flushing, and other side effects are common enough that Dorr et al. documented them in their original 2000 trial.
• Any changes to moles or skin lesions while using Melanotan II warrant prompt dermatological evaluation.
• The creator's casual framing, "once a month, I'll go to the tanning bed," does not reflect the current state of safety evidence.